The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress.
 
Jong-Mu Sun
No Relationships to Disclose
 
Peter C. Enzinger
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Celgene; Coherus Biosciences; Daiichi Sankyo; Five Prime Therapeutics; IDEAYA Biosciences; Istari; Legend Biotech; Lilly; loxo; Merck; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Turning Point Therapeutics; Xencor; Zymeworks
 
Antoine Adenis
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; Bristol-Myers Squibb; Merck; Merck Serono
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology
Research Funding - Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; SERVIER
 
Manish A. Shah
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Oncolys BioPharma (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Jaafar Bennouna
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Research Funding - AstraZeneca; Merck
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Toshihiko Doi
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Oncolys BioPharma; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Daiichi Sankyo; Janssen; Kyowa Hakko Kirin; MSD; Otsuka; Rakuten Medical; Sumitomo Dainippon; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQvia (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Natalyn Nicole Hawk
Employment - Eisai
 
Li Yu
No Relationships to Disclose
 
Sukrut Shah
Employment - Merck
 
Pooja Bhagia
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche
Speakers' Bureau - Hutchison Whampoa; MSD
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)